Domača stranALMKT • EPA
add
Mauna Kea Technologies SA
Prejšnji trg. dan.
0,19 €
Dnevni razpon
0,18 € - 0,19 €
Letni razpon
0,16 € - 0,53 €
Tržna kapitalizacija
12,00 mio. EUR
Povprečni obseg
121,80 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
EPA
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 2,13 mio. | −40,22 % |
Stroški poslovanja | 3,51 mio. | −5,78 % |
Čisti dohodek | −2,34 mio. | −267,42 % |
Čista dobičkovnost prihodkov | −109,77 | −380,03 % |
Earnings per share | — | — |
EBITDA | −1,76 mio. | −559,07 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 3,82 mio. | −39,56 % |
Skupna sredstva | 18,15 mio. | −25,14 % |
Skupne obveznosti | 38,49 mio. | −5,23 % |
Celoten lastniški kapital | −20,34 mio. | — |
Shares outstanding | 64,62 mio. | — |
Razmerje P/B | −0,60 | — |
Donosnost sredstev | −25,45 % | — |
Donosnost kapitala | −56,78 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −2,34 mio. | −267,42 % |
Denar iz dejavnosti | −1,90 mio. | −233,29 % |
Denar iz naložb | 36,50 tis. | 183,91 % |
Denar iz financiranja | −226,50 tis. | −218,90 % |
Neto sprememba denarnih sredstev | −2,09 mio. | −232,96 % |
Prost denarni tok | −802,94 tis. | −487,16 % |
Vizitka
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Generalni direktor
Datum ustanovitve
2000
Spletno mesto
Zaposleni
65
